首页 | 本学科首页   官方微博 | 高级检索  
     

成人T细胞急性淋巴细胞白血病治疗及预后分析
引用本文:黄走方,王婷玉,傅明伟,刘薇,郝牧,邱录贵,邹德慧. 成人T细胞急性淋巴细胞白血病治疗及预后分析[J]. 中国医学科学院学报, 2019, 41(4): 485-491. DOI: 10.3881/j.issn.1000-503X.10807
作者姓名:黄走方  王婷玉  傅明伟  刘薇  郝牧  邱录贵  邹德慧
作者单位:中国医学科学院 北京协和医学院 血液病研究所 血液病医院淋巴瘤中心 实验血液学国家重点实验室,天津 300020
基金项目:十二五国家科技支撑计划项目(2014BAI0912);国家自然科学基金(81630007);中国医学科学院医学与健康科技创新工程(CAMS-2017-I2M-1-005);中国医学科学院医学与健康科技创新工程(CAMS-2016-I2M-3-013)
摘    要:目的 探讨成人T细胞急性淋巴细胞白血病的治疗与预后。方法 回顾性研究2003年1月1日至2017年6月30日中国医学科学院血液病医院淋巴瘤中心收治的68例初治成人T细胞急性淋巴细胞白血病(T-ALL)患者,分析其疗效及预后。结果 68例成人T-ALL患者中位年龄23(14~60)岁,男性多见。第1疗程后完全缓解(CR)率73%,皮质T-ALL的CR率最高,其他T-ALL其次,早期前体T淋巴细胞白血病最低,分别为100%、73%、54%(χ 2=5.712,P=0.058);年龄>35岁病例组首疗程CR率低于≤35岁病例组(40%比79%,χ 2=6.364,P=0.012),性别、白细胞计数各组的首疗程CR率比较差异无统计学意义。第2疗程后总CR率93%。化疗、自体造血干细胞移植(auto-SCT)、异基因造血干细胞移植(allo-SCT)中位无进展生存时间分别为10个月、24个月、未达到(P=0.002)。5年总生存率为25%,化疗、auto-SCT、allo-SCT中位OS分别为24、34、30个月(P=0.007),5年总生存率分别为9%、33%、38%(P=0.037)。将性别、年龄、白细胞计数、达CR时间>4周、T亚型等因素进行多因素分析,结果显示白细胞计数≥100×10 9/L是影响无复发生存时间的危险因素(风险比2.540,95%CI=1.058~6.099,P=0.037)。结论 成人T-ALL患者预后差,造血干细胞移植可能改善患者预后。

关 键 词:白血病  淋巴样  治疗  预后  
收稿时间:2018-08-26

Treatment and Prognosis of Adult T Cell Acute Lymphoblastic Leukemia
HUANG Zoufang,WANG Tingyu,FU Mingwei,LIU Wei,HAO Mu,QIU Lugui,ZOU Dehui. Treatment and Prognosis of Adult T Cell Acute Lymphoblastic Leukemia[J]. Acta Academiae Medicinae Sinicae, 2019, 41(4): 485-491. DOI: 10.3881/j.issn.1000-503X.10807
Authors:HUANG Zoufang  WANG Tingyu  FU Mingwei  LIU Wei  HAO Mu  QIU Lugui  ZOU Dehui
Affiliation:Department of Lymphoma Center,State Key Laboratory of Experimental Hematology,Institute of Hematology and Blood Diseases Hospital,CAMS and PUMC,Tianjin 300020,China
Abstract:Objective To analyze the treatment and prognosis of T cell acute lymphoblastic leukemia(T-ALL)in adults. Method The clinicobiogical and survival data of 68 adult patients with newly diagnosis T-ALL were retrospectively analzyed. Results The median age of these 68 patients was 23 years(14-60 years).T-ALL was more common in men(81%).After the first cycle of treatment,complete remission was achieved in 50 patients(73%).The highest complete remission(CR) rate was in patients with cortex T-ALL(100%),followed by other T-ALL(73%)and early T-cell precursor lymphoblastic leukemia(54%),(χ 2=5.712,P=0.058).The CR rate for adults aged >35 years was significantly lower than that of patients aged ≤ 35 years(40% vs. 79%,χ 2=6.364,P=0.012).The overall CR rate after the second treatment course was 93%.For patients treated with chemotherapy,autograft hematopoietic stem cell transplantation(auto-SCT),and allogeneic SCT,the median relapse free survival was 10 months,24 months,and not reached,respectively(P=0.002).The 5-year overall survival rate was 25% for all patients;for patients treated with chemotherapy,auto-SCT and allogeneic SCT,the median overall survival was 24 months,34 months,and 30 months,respectively(P=0.007),and the 5-year overall survival rate was 9%,33%,and 38%(P=0.037).Multivariate analysis showed leukocyte count ≥100×10 9/L was a risk factor for decreased relapse free survival(risk ratio 2.540,95%CI=1.058-6.099,P=0.037). Conclusion Adult T-ALL patients have poor prognosis,which may be improved by SCT.
Keywords:leukemia  lymphoid  treatment  prognosis  
点击此处可从《中国医学科学院学报》浏览原始摘要信息
点击此处可从《中国医学科学院学报》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号